Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

3 Humongous Health-Care Stocks This Week: Infinity Pharmaceuticals Inc. (INFI)

There’s power in positive thinking. The late author Norman Vincent Peale made plenty of money off that philosophy. Some investors made lots of money over the last five days thanks to positive thinking about these three health-care stocks that saw humongous gains.

Optimism from Morgan Stanley (NYSE:MS)
Analysts at Morgan Stanley must have read Peale’s book. On Tuesday, the investment firm upgraded Infinity Pharmaceuticals Inc. (NASDAQ:INFI) to “overweight” and set a new price target of $47 per share. Infinity shares responded by jumping nearly 18% for the week.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)What sparked Morgan Stanley’s glowing endorsement? The main reason seems to be Infinity’s experimental PI3K inhibitor IPI-145. Infinity reported positive results from its phase 1 trial of IPI-145 targeting treatment of blood cancers back in December. The company plans to advance the drug into phase 2 studies for this indication in 2013. Infinity also has mid-stage trials either planned or in progress for IPI-145 in treating asthma and rheumatoid arthritis.

Such exuberance might seem a little on the irrational side. However, my guess is that Morgan Stanley and others are probably looking at the success that other companies have had with kinase inhibitors. Privately held Calistoga Pharmaceuticals was snatched up by Gilead Sciences, Inc. (NASDAQ:GILD) in 2011 based on early success with its PI3K inhibitor CAL-101. Pharmacyclics, Inc. (NASDAQ:PCYC) has seen shares surge more than 65% over the past three months on good news with its Bruton’s tyrosine kinase inhibitor, ibrutinib.

Positive momentum
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares popped 13% this week. There wasn’t really any news from the company this week; instead, the nice gains appear to be a continuation from momentum that started last week.

A Valentine’s Day announcement had Celldex investors feeling good about prospects for the company’s experimental drug CDX-301. A phase 1 study of the drug in hematopoietic stem cell transplantation yielded positive results. Volunteers in the study who took CDX-301 experienced large increases in CD34+ and dendritic cells, findings that bode well for improved transplant outcomes.

Celldex also has other potential winners that are farther along in development. In November, the company announced positive phase 2 results for rindopepimut in treating EGFRvIII-positive glioblastoma. It also released good results in December from a phase 2 study of CDX-011 in treating breast cancer.

More happy thoughts
Another investment firm had happy thoughts this week, too. Mizuho upgraded Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) from “neutral” to “buy” and raised its price target to $41 per share. Questcor’s shares were up 8% for the week.